Undecimal Bio develops delivery molecules that help RNA medicines reach specific tissues, with initial research programmes in kidney and vascular disease.
IC
IQ Capital
Activity from announced rounds
Activity in this selectionUnited Kingdom · Oct 23, 2026 · Jan 1, 2026
- Rounds participated in
- 8
- Confirmed lead rounds
- 1 6 roles undisclosed
- New companies
- 8 First participation on record · 0 follow-on
- Funding in participating rounds
- $266.7M 8 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
8 in this selectionUndecimal Bio
$18MSeed
LeadMindgard
Mindgard helps enterprise security teams find and address vulnerabilities in AI models, applications and agents.
$30MSeries A
ParticipantIMU Biosciences
Profiles human immune systems using multi-omic analysis and machine learning for disease research.
$53MSeries A
Role not disclosedRevEng.AI
Provides binary-level AI analysis of compiled software to detect hidden vulnerabilities and supply chain threats
$15MSeries A
Role not disclosedImperagen
Uses quantum physics simulation and AI to engineer high-performance enzymes for pharma and industrial markets
£5MSeed
Role not disclosedNyobolt
Develops ultra-fast-charging battery systems for autonomous robots, physical AI applications, and AI data center power infrastructure
$60MSeries C
Role not disclosedRivan
Develops synthetic fuel infrastructure for domestic energy production
$34MUndisclosed
Role not disclosedIsembard
Develops software to automate manufacturing of key component parts for industries
$50MSeries A
Role not disclosed